This message was posted by a user wishing to remain anonymous
Dear Colleagues,
Is there a mutual recognition agreement (MRA) between US and China for biologics (mAbs) clinical supplies testing?
For a clinical supply batch (CTM) of investigational biologic (IMP) in China clinical study: if a QC release test (e.g. assay/purity) is performed at a US/EU testing site, is it a China regulatory/QC requirement that the test be repeated at a China QC testing site for the batch/lot to be acceptable for use in the China clinical study?
To clarify, I am not asking about the requirement for China NMPA Lab which does its own verification testing.
Thanks in advance